Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Rossignol

Showing results (61-70 of 541) with videos related to

Pageof 55
Sort By:
International Journal of Cardiology|November 26, 2019
Insulin-like growth factor binding protein 2: A prognostic biomarker for heart failure hardly redundant with natriuretic peptidesNicolas Girerd, Emmanuel Bresso, Marie-Dominique Devignes, et al.
European Journal of Heart Failure|September 10, 2016
A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysisNicolas Girerd, João Pedro Ferreira, Patrick Rossignol, et al.
Clinical Science (London, England : 1979)|June 29, 2022
The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney diseaseJonatan Barrera-Chimal, Casimiro Gerarduzzi, Patrick Rossignol, et al.
Lancet (London, England)|August 3, 2020
Individual patient risk assessment and cost-benefit analysis of patiromer in AMBER - Authors' replyRajiv Agarwal, Patrick Rossignol, William B White, et al.
Journal of Hypertension|January 16, 2002
Proteinuria in renal artery occlusion is related to active renin concentration and contralateral kidney sizePatrick Rossignol, Gilles Chatellier, Michel Azizi, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 13, 2020
Spironolactone for resistant hypertension in advanced chronic kidney disease-red, amber or green?Rajiv Agarwal, Patrick Rossignol, Bryan Williams, et al.
American Journal of Hypertension|February 11, 2021
Impact of Anti-hypertensive Therapy in the Sexual Health of Men and Women: An Analysis From the SPRINT TrialJoão Pedro Ferreira, Michael Böhm, Patrick Rossignol, et al.
European Journal of Heart Failure|July 23, 2015
Geographic differences in heart failure trialsJoão Pedro Ferreira, Nicolas Girerd, Patrick Rossignol, et al.
International Heart Journal|January 18, 2021
Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic ResistanceNicolas Girerd, Matthieu Aubry, Pierre Lantelme, et al.
Lancet (London, England)|March 13, 2019
Heart failure drug treatmentPatrick Rossignol, Adrian F Hernandez, Scott D Solomon, et al.
Pageof 55

Showing results (61-70 of 541) with videos related to

Sort By:
Pageof 55
International Journal of Cardiology|November 26, 2019
Insulin-like growth factor binding protein 2: A prognostic biomarker for heart failure hardly redundant with natriuretic peptidesNicolas Girerd, Emmanuel Bresso, Marie-Dominique Devignes, et al.
European Journal of Heart Failure|September 10, 2016
A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysisNicolas Girerd, João Pedro Ferreira, Patrick Rossignol, et al.
Clinical Science (London, England : 1979)|June 29, 2022
The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney diseaseJonatan Barrera-Chimal, Casimiro Gerarduzzi, Patrick Rossignol, et al.
Lancet (London, England)|August 3, 2020
Individual patient risk assessment and cost-benefit analysis of patiromer in AMBER - Authors' replyRajiv Agarwal, Patrick Rossignol, William B White, et al.
Journal of Hypertension|January 16, 2002
Proteinuria in renal artery occlusion is related to active renin concentration and contralateral kidney sizePatrick Rossignol, Gilles Chatellier, Michel Azizi, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 13, 2020
Spironolactone for resistant hypertension in advanced chronic kidney disease-red, amber or green?Rajiv Agarwal, Patrick Rossignol, Bryan Williams, et al.
American Journal of Hypertension|February 11, 2021
Impact of Anti-hypertensive Therapy in the Sexual Health of Men and Women: An Analysis From the SPRINT TrialJoão Pedro Ferreira, Michael Böhm, Patrick Rossignol, et al.
European Journal of Heart Failure|July 23, 2015
Geographic differences in heart failure trialsJoão Pedro Ferreira, Nicolas Girerd, Patrick Rossignol, et al.
International Heart Journal|January 18, 2021
Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic ResistanceNicolas Girerd, Matthieu Aubry, Pierre Lantelme, et al.
Lancet (London, England)|March 13, 2019
Heart failure drug treatmentPatrick Rossignol, Adrian F Hernandez, Scott D Solomon, et al.
Pageof 55